The same year, Wu et al. confirmed the presence of elevated miR-21 levels in high-fat diet-fed mice, where it promoted hepatic lipid accumulation and cancer progression by interacting with the Hbp1-p53-Srebp1c pathway, thus endorsing miR-21 as a link between NAFLD and HCC but also as a potential therapeutic target for both disorders [151]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.